Challenge 1: Prevention Vaccines
We launched Grand Challenge in 2015 calling on the greatest scientific minds from around the world to take on the toughest challenges in cancer research. Every two years we launch a new set of challenges which, if solved, would transform the cancer landscape.
The power of the immune system is already being used to treat cancer. Now we'd like to see vaccines that can prevent cancer from developing in the first place.
In 2015, one of our Grand Challenges was:
DEVELOP VACCINES TO PREVENT NON-VIRAL CANCERS
This challenge is now closed for applications.
Can we develop a jab to prevent cancer?
Vaccines already exist that prevent cancers caused by infection, such as against the human papilloma virus that causes some cervical cancers. But this challenge is to develop vaccines that work against non-viral cancers, which are caused by faults in our DNA that accumulate over time.
That’s what really makes this a Grand Challenge. Because cancer is a disease of the body’s own cells, it is more challenging to coax the immune system to recognize and eliminate early stage cancers, where the difference between healthy cells and abnormal cells might be very small.
But the promise is huge: imagine if we could vaccinate against cancer as we do for infectious diseases such as TB and measles. Grand Challenge could make this a reality.
Although the idea of vaccines to prevent cancer is not new, it is now closer to the realm of possibility thanks to recent advances in treating cancer using immune-based approaches.
The results of these treatments have clearly demonstrated that the immune system can recognise tumour antigens and generate impressive clinical responses. Current approaches include immune checkpoint blockade, adoptive T cell therapies, chimeric antigen receptor-expressing T cells and therapeutic vaccines, among others.
The success so far in demonstrating effective immune responses to cancer in the treatment setting provides the impetus to consider developing preventive vaccines for one or multiple forms of the disease.
These vaccines would be designed to stimulate the production of memory cells that could subsequently recognize and eliminate early-stage cancers or pre-neoplastic lesions when they appear.
There are a number of fundamental gaps in our knowledge of tumour immunology that could be filled by a team working on this challenge, such as whether the immune response to cancer is limited to neo-antigens (antigens expressed on cancer cells as a result of cancer-specific mutations) or mis-expressed self-antigens (antigens that exist on normal cells, but are altered or present in higher amounts on tumour cells.)
We are also yet to understand when and how the immune response is triggered by the presence of cancer cells, how the immune system sees them, why common mutational changes in cancer are not normally recognised by the immune system and whether immune responses can be stimulated against these.
Finally, there is the key question of whether the immune system’s tolerance of self-antigens can be broken without inducing autoimmunity.